ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Dezembro 2023 - 6:30PM
Business Wire
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that the compensation committee of the Company’s
Board of Directors (the “Compensation Committee”) approved,
effective as of November 30, 2023, the grant of restricted stock
units (“RSUs”) covering 112,252 shares of ImmunoGen’s common stock
under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as
amended (the “Inducement Plan”) to twelve new employees.
The Inducement Plan is used exclusively for the grant of equity
awards to individuals who were not previously employees of
ImmunoGen (or following a bona fide period of non-employment), as
an inducement material to such individual’s entering into
employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the
Nasdaq Listing Rules.
Each RSU will vest as to 25% of the shares underlying the RSU
award on the first anniversary of the grant date and as to an
additional 25% of the shares underlying the RSU award annually
thereafter, subject to the employee’s continued employment on each
vesting date. Each RSU is subject to the terms and conditions of
the Inducement Plan and the terms and conditions of an RSU
agreement covering the grants.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug
conjugates to improve outcomes for cancer patients. By generating
targeted therapies with enhanced anti-tumor activity and favorable
tolerability profiles, we aim to disrupt the progression of cancer
and offer our patients more good days. We call this our commitment
to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231201600597/en/
INVESTOR RELATIONS CONTACT ImmunoGen Anabel Chan
781-895-0600 anabel.chan@immunogen.com
MEDIA CONTACTS ImmunoGen Courtney O’Konek 781-895-0600
courtney.okonek@immunogen.com OR FTI Consulting Robert Stanislaro
212-850-5657 robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
ImmunoGen (NASDAQ:IMGN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024